Last year we set up an industry taskforce to look at this problem. Twelve years after the publication of the 2000 UK AMR Strategy, we were pleased to see that Department of Health announced its intention to review their approach to dealing with antimicrobial resistance. We responded to the draft strategy with our recommendations but we have been disappointed by the continual delays in publishing the updated strategy.
Antimicrobial resistance is a serious and growing problem and we believe that for there to be a continual supply of effective antibiotics, a comprehensive review of the research and development environment and good stewardship are required urgently. Effective stewardship alone will not be sufficient to meet the antibiotic challenge. The pharmaceutical industry has some new antibiotics coming through its pipelines but until all interested parties work together to understand the commercial barriers to the development of new antibiotics we won’t address this challenge effectively.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
Notes to editors
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.